Q32 Bio to Participate in Upcoming September Investor Conferences
Q32 Bio Inc. (Nasdaq: QTTB), a clinical stage biotechnology company, has announced its participation in three upcoming investor conferences in September 2024. The company, which focuses on developing biologic therapeutics to restore immune homeostasis, will be present at:
1. Morgan Stanley 22nd Annual Global Healthcare Conference on September 5 in New York, NY
2. 2024 Cantor Fitzgerald Global Healthcare Conference on September 17 in New York, NY (presentation at 3:40 p.m. E.T.)
3. Stifel 2024 Virtual Immunology and Inflammation Summit on September 18 (virtual presentation at 11:30 a.m. E.T.)
Webcasts of the Cantor and Stifel presentations will be available on Q32 Bio's website, with archived replays accessible for 30 days after the events.
Q32 Bio Inc. (Nasdaq: QTTB), una compagnia biotecnologica in fase clinica, ha annunciato la sua partecipazione a tre prossime conferenze per investitori a settembre 2024. L'azienda, che si concentra sullo sviluppo di terapie biologiche per ripristinare l'omeostasi immunitaria, sarà presente a:
1. 22ª Conferenza Globale sulla Sanità di Morgan Stanley il 5 settembre a New York, NY
2. Conferenza Globale sulla Sanità 2024 di Cantor Fitzgerald il 17 settembre a New York, NY (presentazione alle 15:40 E.T.)
3. Summit Virtuale su Immunologia e Infiammazione 2024 di Stifel il 18 settembre (presentazione virtuale alle 11:30 E.T.)
I webcast delle presentazioni di Cantor e Stifel saranno disponibili sul sito web di Q32 Bio, con repliche archiviate accessibili per 30 giorni dopo gli eventi.
Q32 Bio Inc. (Nasdaq: QTTB), una empresa de biotecnología en etapa clínica, ha anunciado su participación en tres próximas conferencias para inversores en septiembre de 2024. La compañía, que se enfoca en desarrollar terapias biológicas para restaurar la homeostasis inmune, estará presente en:
1. 22ª Conferencia Global de Salud de Morgan Stanley el 5 de septiembre en Nueva York, NY
2. Conferencia Global de Salud 2024 de Cantor Fitzgerald el 17 de septiembre en Nueva York, NY (presentación a las 3:40 p.m. E.T.)
3. Cumbre Virtual de Inmunología e Inflamación 2024 de Stifel el 18 de septiembre (presentación virtual a las 11:30 a.m. E.T.)
Las transmisiones de las presentaciones de Cantor y Stifel estarán disponibles en el sitio web de Q32 Bio, con repeticiones archivadas accesibles durante 30 días después de los eventos.
Q32 Bio Inc. (Nasdaq: QTTB), 임상 단계의 생명공학 회사가 2024년 9월에 열리는 세 가지 투자자 회의에 참여한다고 발표했습니다. 이 회사는 면역 항상성을 회복하기 위한 생물학적 치료제 개발에 주력하고 있으며, 다음과 같은 행사에 참석할 예정입니다:
1. 모건 스탠리 제22회 글로벌 헬스케어 회의 9월 5일 뉴욕, NY에서
2. 2024 캔터 피츠제럴드 글로벌 헬스케어 회의 9월 17일 뉴욕, NY에서 (오후 3:40 E.T. 발표)
3. 스틸 펠 2024 가상 면역학 및 염증 정상 회담 9월 18일 (오후 11:30 E.T. 가상 발표)
캔터와 스틸의 발표 웹캐스트는 Q32 Bio 웹사이트에서 제공되며, 행사 후 30일 동안 아카이브된 재생이 가능합니다.
Q32 Bio Inc. (Nasdaq: QTTB), une entreprise de biotechnologie en phase clinique, a annoncé sa participation à trois prochaines conférences pour investisseurs en septembre 2024. L'entreprise, qui se concentre sur le développement de thérapies biologiques pour restaurer l'homéostasie immunitaire, sera présente aux événements suivants :
1. 22ème Conférence Mondiale sur la Santé de Morgan Stanley le 5 septembre à New York, NY
2. Conférence Mondiale sur la Santé 2024 de Cantor Fitzgerald le 17 septembre à New York, NY (présentation à 15h40 E.T.)
3. Sommet Virtuel sur l'Immunologie et l'Inflammation 2024 de Stifel le 18 septembre (présentation virtuelle à 11h30 E.T.)
Les rediffusions des présentations de Cantor et Stifel seront disponibles sur le site web de Q32 Bio, avec des replays archivés accessibles pendant 30 jours après les événements.
Q32 Bio Inc. (Nasdaq: QTTB), ein Biotechnologieunternehmen in der klinischen Phase, hat seine Teilnahme an drei bevorstehenden Investorenkonferenzen im September 2024 angekündigt. Das Unternehmen, das sich auf die Entwicklung biologischer Therapien zur Wiederherstellung der Immunhomöostase konzentriert, wird an folgenden Veranstaltungen teilnehmen:
1. 22. Jahrestagung zur globalen Gesundheitsversorgung von Morgan Stanley am 5. September in New York, NY
2. 2024 Cantor Fitzgerald globale Gesundheitsversorgungskonferenz am 17. September in New York, NY (Präsentation um 15:40 Uhr E.T.)
3. Stifel 2024 Virtuelles Immunologie- und Entzündungsgipfeltreffen am 18. September (virtuelle Präsentation um 11:30 Uhr E.T.)
Webcasts der Präsentationen von Cantor und Stifel werden auf der Website von Q32 Bio verfügbar sein, und archivierte Aufzeichnungen sind 30 Tage nach den Veranstaltungen zugänglich.
- None.
- None.
Morgan Stanley 22nd Annual Global Healthcare Conference
Date: Thursday, September 5, 2024
Location:
2024 Cantor Fitzgerald Global Healthcare Conference
Date: Tuesday, September 17, 2024
Presentation Time: 3:40 p.m. E.T.
Location:
Stifel 2024 Virtual Immunology and Inflammation Summit
Date: Wednesday, September 18, 2024
Presentation Time: 11:30 a.m. E.T.
Location: Virtual
A webcast of the Cantor and Stifel presentations will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. Archived replays will be available for 30 days following the event.
About Q32 Bio
Q32 Bio is a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Q32 Bio's lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives.
Q32 Bio's program for adaptive immunity, bempikibart (ADX-914), is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases. It is being evaluated in two Phase 2 trials for the treatment of atopic dermatitis and alopecia areata. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases. Q32 Bio's program for innate immunity, ADX-097, is based on a novel platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade – a key differentiator versus current complement therapeutics. Q32 Bio has completed a first-in-human, Phase 1 ascending dose clinical study of ADX-097 in healthy volunteers.
For more information, visit www.Q32Bio.com.
Availability of Other Information About Q32 Bio
Investors and others should note that we communicate with our investors and the public using our company website www.Q32Bio.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly Twitter) and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Contacts:
Investors: Brendan Burns
Media: Sarah Sutton
Argot Partners
212.600.1902
Q32Bio@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/q32-bio-to-participate-in-upcoming-september-investor-conferences-302233260.html
SOURCE Q32 Bio
FAQ
What investor conferences will Q32 Bio (QTTB) attend in September 2024?
When and where will Q32 Bio (QTTB) present at the Cantor Fitzgerald Global Healthcare Conference?
Will Q32 Bio's (QTTB) presentations at the September 2024 conferences be available online?
What is the focus of Q32 Bio (QTTB) as a biotechnology company?
